Motif Bio's US listing plans delayed

Motif Bio said on Tuesday that it is delaying its planned listing on the Nasdaq in the US “as a result of market conditions”.

The clinical stage biopharmaceutical company said it intends to continue to engage with investors and will provide an update in due course.

The company had been hoping to raise up to $60m from US investors in the process to help fund phase III clinical trials of its flagship iclaprim drug.

At 1045 BST, shares were down 19% to 51.12p.